Study: Fujirebio's HE4 test helps identify which women with pelvic masses have ovarian cancer
This article was originally published in Clinica
Executive Summary
Fujirebio Diagnostics has identified a biomarker that could distinguish between benign and malignant pelvic masses when used in combination with the current gold-standard ovarian cancer diagnostic, CA125.